Compounds > zalcitabine
Page last updated: 2024-08-22

zalcitabine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

zalcitabine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amblard, F; Amiralaei, S; Bassit, L; Bobeck, D; Cho, JH; Coats, SJ; Detorio, M; Ehteshami, M; McBrayer, TR; Pradere, U; Schinazi, RF; Tao, S; Whitaker, T; Zhang, HW; Zhou, L1
Chiche, L; Cretel, E; Durand, JM; Figuarella-Branger, D; Jean, R1
Chinitz, MA1
Aoki, M; Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamaguchi, M; Yamamoto, Y; Yasuoka, A; Yasuoka, C1

Other Studies

4 other study(ies) available for zalcitabine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

ArticleYear
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
    Journal of medicinal chemistry, 2015, Apr-23, Volume: 58, Issue:8

    Topics: 2-Aminopurine; Amides; Antiviral Agents; Cell Line; Cells, Cultured; Guanosine Triphosphate; Hepacivirus; Hepatitis C; Humans; Methylation; Phosphoric Acids; Prodrugs; Ribonucleosides

2015
[Central nervous system HIV-associated polyarteritis nodosa: long-term outcome].
    La Revue de medecine interne, 2006, Volume: 27, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Central Nervous System Infections; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Polyarteritis Nodosa; Stavudine; Time Factors; Treatment Outcome; Virus Replication; Zalcitabine

2006
Ribavirin for chronic hepatitis C.
    Annals of internal medicine, 1996, Oct-15, Volume: 125, Issue:8

    Topics: Antiviral Agents; Chronic Disease; Hepatitis C; Humans; Lamivudine; Ribavirin; Zalcitabine

1996
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
    Japanese journal of infectious diseases, 1999, Volume: 52, Issue:6

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy, Combination; Glycine; Glycyrrhetinic Acid; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zalcitabine; Zidovudine

1999